CN1389207A - Tetradic injection for treating hepatocirrhosis and liver ascites and its compounding process - Google Patents
Tetradic injection for treating hepatocirrhosis and liver ascites and its compounding process Download PDFInfo
- Publication number
- CN1389207A CN1389207A CN 02114560 CN02114560A CN1389207A CN 1389207 A CN1389207 A CN 1389207A CN 02114560 CN02114560 CN 02114560 CN 02114560 A CN02114560 A CN 02114560A CN 1389207 A CN1389207 A CN 1389207A
- Authority
- CN
- China
- Prior art keywords
- injection
- injecta
- tetrad
- mixture
- cirrhotic ascites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The intraperitoneal injection for curing ascites due to cirrhosis is formed from combination of dopamine injection, frusemide injection, dimy injection and cephazoline injection, and its operation includes the following procedures: hypersensitive test, equipment disinfection, batch quantification, ordering and mixing and time-limiting injection. Its preparation process is simple and its therapeutic effect is obvious.
Description
The present invention treats cirrhotic ascites tetrad mixture injecta and preparing process belongs to special for treating because of cirrhotic ascites medicine and preparing process thereof that hypofunction of liver causes, relates in particular to a kind of only the injection prescription and preparing process thereof of with medicament treatment cirrhotic ascites of need not drawing water from the abdominal cavity.
What the treatment cirrhotic ascites adopted at present is the operative treatment that draws water from the abdominal cavity, defectives such as operative treatment exists not only that the patient suffering adds, wound easy infection, complication are many, and owing to albumen in patient's ascites excretes with ascites, it is out of proportion to have aggravated interior albumin of patient's body and globulin, and the treatment phase is prolonged.Single extraction ascites operation, little to treatment cash sclerosis ascites effect, cure the symptoms, not the disease, promptly increased the patient treatment expense, the condition of illness relapse rate is higher again.
The declarer is by clinical research for many years, make treatment cirrhotic ascites " tetrad mixture injecta " and treatment cirrhotic ascites " perfect electuary ", can be in clinical simultaneously in various degree cirrhotic ascites patient in conjunction with application, the outer notes taken orally, treating both the principal and secondary aspects of a disease, reach the short effect that can promote liver function recovery again of abdominal cavity ascites healing period, alleviate the patient suffering, and reduce the patient medical expense greatly.
The present invention treats cirrhotic ascites tetrad mixture injecta and preparing process thereof, provide prescription rationally for the cirrhotic ascites patient, each prescription medicament complementary action is remarkable, the novel easily again Mixed Pharmacy of treatment operation, not only technology is easy for preparation treatment cirrhotic ascites tetrad mixture injecta, and in prescription, select medicine few, quantitatively accurately, the program of making up a prescription is reasonable, make the even combination of all explosive components, behind the patient infusion, impel ascites to discharge from urethra with urine gradually, reduced the loss of body internal protein, can thoroughly remove abdominal cavity ascites in general 5-8 days, as treat phase oral " perfect electuary " partner treatment simultaneously, can accelerate liver function recovery, treating both the principal and secondary aspects of a disease is got well the patient about first quarter moon.
In order to realize the foregoing invention purpose, its treatment cirrhotic ascites tetrad mixture injecta and preparing process thereof are as follows:
1, treatment cirrhotic ascites tetrad mixture injecta is formulated by dopamine, furosemide, DIMI and four kinds of injection of cefazolin, and treatment cirrhotic ascites tetrad mixture injecta respectively becomes agent prescription amount, and effectively degree is as follows:
| Group medicine title | Formula ratio (milliliter) | Content (%) |
| Injection sample | ????45 | ????45 |
| Furosemide injection | ????50 | ????50 |
| The DIMI injection | ????4 | ????4 |
| The cefazolin injection | ????1 | ????1 |
| Add up to | ????100 | ????100 |
2. treatment cirrhotic ascites tetrad mixture injecta is prepared and using method:
1. make hypersensitive test to the patient, as belong to feminine gender, can determine medication.
2. get medicament and needle tubing ready, and to the needle tubing sterilization.
3. prepare and use at twice and carry out, for the first time by the medication formula ratio half, suck the DIMI injection earlier with needle tubing in order, the back sucks furosemide injection, resorb cefazolin injection sucks injection sample at last.
4. injection medicament after sterilization is carried out in abdominal cavity, 1/3rd outsides under patient's abdominal part umbilicus and the last sour jujube bone line was annotated in 3-5 minute.
5. in 24-72 hour, inject for the second time with same preparation and using method.According to patient age, the state of an illness and health, amount of preparation can suitably be reduced.
Cirrhotic ascites is a commonly encountered diseases, mostly be cardiac cirrhosis, on form, be micronodular cirrhosis, this class liver cirrhosis all is hepatosplenomegaly and the serum albumin amount reduces, cause albumin and globulin out of proportion, impel hepatocyte distortion widely and downright bad gradually, fibrous tissue diffusivity hypertrophy, though liver function injury is still not serious, but having caused that the abdominal cavity is poly-stays hydrops, and involves other system in the body, treats as untimely, abdominal cavity ascites stagnates for a long time and ties, liver function further goes down, and will cause liver to be out of shape gradually and the more multisystem multiple performance of getting involved, and in the prescription medicine: the furosemide in the furosemide injection influences the formation of renal medulla hyperosmotic state and keeps, weaken the concentrating function of urine, accelerated abdominal cavity moisture content and discharged in a large number from urethra; Dopamine in the injection sample promotes the visceral vessel expansion, and blood flow increasing all increases renal blood flow and glomerular filtration rate, thereby impels urine amount and sodium discharge capacity to increase, and improves not circulation slightly, also obviously impels the urine amount to increase; The cefazolin injection is the similar cephalo ammonia of an antimicrobial spectrum card, and multiple pathogenic bacteria is had resistance, especially the urogenital infections due to the sensitive organism is had resistance; The DIMI injection has the function of antiinflammatory and control skin allergy, makes steady Kang Fu of patient treatment phase.
Modern pharmacology proves, more than four class injection share each medicine and have complementary functions, play the merit of diuresis draining altogether, and stop courses of infection and control skin allergy, the abdominal cavity ascites that liver cirrhosis is caused is discharged from urethra rapidly, draws water to perform the operation with the abdominal cavity and compares, and has reduced the protein loss, suitably oral again " perfect electuary ", the outer notes taken orally, can improve albumin and globulin ratio and total serum protein level rapidly, impels the obvious persistence expansion of little blood vessel in the liver, alleviate the hole blood capillaryization, alleviate microcirculation resistance in the liver, suppress fibrohistiocytic's hypertrophy, can eliminate thoracic cavity ascites rapidly again, avoid inflammation to take place, impel the cirrhotic ascites patient complete rapidly.
Treatment cirrhotic ascites tetrad mixture injecta prescription is through long-term clinical application and update, select for use each medicine to be mixed, its active ingredient concentrates on one, and compatibility is scientific and reasonable, inject complementary the use significantly behind the thoracic cavity, can make effectively that ascites excretes from urethra safety no pain rapidly in the abdominal cavity, easy to operate, effect is obvious, effective percentage and cure rate are all above 90%, this treatment cirrhotic ascites tetrad mixture injecta cost is low, and the curative effect height has no side effect.
Claims (2)
1, the present invention treats cirrhotic ascites tetrad mixture injecta and preparing process thereof, it is characterized in that treating cirrhotic ascites tetrad mixture injecta by injection sample, furosemide injection, the DIMI injection, the cefazolin injection side of closing composition, the operation sequence of preparation and treatment cirrhotic ascites tetrad mixture injecta is as described below: earlier the patient is carried out the allergy test, and with the injection sterilization of instruments, operation is carried out at twice, each quantitative respectively with 1/2nd by prescription, be docile and obedient preface at every turn and at first suck the DIMI injection, the resorb furosemide injection, suck the cefazolin injection immediately, suck injection sample at last, injection medicament again after ventrolateral compartment carries out sterilization outside 1/3rd places under patient's abdominal part umbilicus and last sour jujube bone line, annotated in 3-5 minute, the double injection interval time is 24-72 hour.
2, treatment liver cirrhosis tetrad mixture injecta as claimed in claim 1 and preparing process thereof, it is as follows to it is characterized in that treating the effective degree of each prescription of cirrhotic ascites Tetradic injection:
Injection sample 45 furosemide injections explain 50
DIMI injection 4 cefazolin injection 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02114560 CN1389207A (en) | 2002-05-08 | 2002-05-08 | Tetradic injection for treating hepatocirrhosis and liver ascites and its compounding process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02114560 CN1389207A (en) | 2002-05-08 | 2002-05-08 | Tetradic injection for treating hepatocirrhosis and liver ascites and its compounding process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1389207A true CN1389207A (en) | 2003-01-08 |
Family
ID=4743162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02114560 Pending CN1389207A (en) | 2002-05-08 | 2002-05-08 | Tetradic injection for treating hepatocirrhosis and liver ascites and its compounding process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1389207A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021096755A1 (en) * | 2019-11-15 | 2021-05-20 | Martin Pharmaceuticals, Inc. | Methods of treating ascites |
-
2002
- 2002-05-08 CN CN 02114560 patent/CN1389207A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021096755A1 (en) * | 2019-11-15 | 2021-05-20 | Martin Pharmaceuticals, Inc. | Methods of treating ascites |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102015602A (en) | Minocycline compounds and methods of use thereof | |
| Brown et al. | Recurrent hyperkalaemia due to selective aldosterone deficiency: correction by angiotensin infusion | |
| CN108524519A (en) | New application of M L N4924 in preparing medicine for treating diabetes and/or obesity | |
| CN1389207A (en) | Tetradic injection for treating hepatocirrhosis and liver ascites and its compounding process | |
| CN1739538A (en) | Suppository for teating mycotic vaginitis | |
| CN113332327A (en) | Application of American ginseng and astragalus preparation in preparing product for improving immunity | |
| JPH10114665A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same | |
| CN106902175A (en) | A kind of Chinese medicine ointment for treating perianal eczema | |
| CN102028873B (en) | Tannin berberine gel for treating cervical erosion and preparation process thereof | |
| RU2741247C1 (en) | Method for preventing peritoneal adhesions of a female pelvis | |
| CN115414414B (en) | Traditional Chinese medicine composition and nose washing agent as well as preparation method and application thereof | |
| CN102526413B (en) | Bladder care irrigation solution and preparation method thereof | |
| SU1586712A1 (en) | Method of treatment of flaccid complications of gonorrhea | |
| CN105395671A (en) | Lightyellow sophora root-common cnidium fruit lotion used for treating damp-heat downward flow type colpitis and preparation method thereof | |
| RU2195928C2 (en) | Method for antibioticotherapy | |
| CN105106431A (en) | Traditional Chinese medicine perfusion agent for treating cow ovarian quiescence and persistent corpus luteum infertility and preparation method thereof | |
| de Moura Santos et al. | Surgery Research Journal | |
| Hurwitz | NONALLERGIC ASTHMA—Differential Diagnosis and Treatment | |
| RU2224531C2 (en) | Agent for treatment of chronic pyelonephritis | |
| SU1572633A1 (en) | Method of treating chronic pyelonephritis | |
| Naber et al. | Serum cortisol correlates with depression score after open-heart surgery | |
| WO2021187968A1 (en) | Pharmaceutical kit and method of treating inflammatory processes | |
| CN117257824A (en) | Application of MiR-424 in preparation of products for treating sepsis | |
| SU1560221A1 (en) | Method of treating infectious-allergic rhinosinuitis | |
| Holowaychuk et al. | Peritoneal dialysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |